WESTMINSTER, Colo., June 7 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (Nasdaq: ALTH) today announced that the Company will
participate in the 2006 Needham & Co. Biotechnology Conference, to be held
June 14th - 15th in New York City. Paul L. Berns, the Company's President
and Chief Executive Officer, will give a 25-minute corporate overview on
Wednesday, June 14th at 1:30 PM ET.
The presentation will be webcast live and may be accessed by visiting
the Allos website at http://www.allos.com. A replay of the webcast will also be
available on the Company's website until Friday, June 30, 2006.
About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company
focused on developing and commercializing innovative small molecule
therapeutics for the treatment of cancer. The Company's lead product
candidate, EFAPROXYN(TM) (efaproxiral), is a synthetic small molecule
designed to sensitize hypoxic, or oxygen-deprived, tumor tissue during
radiation therapy. EFAPROXYN is currently being evaluated as an adjunct to
whole brain radiation therapy in a pivotal Phase 3 trial in women with
brain metastases originating from breast cancer. The Company's other
product candidates are: PDX (pralatrexate), a small molecule
chemotherapeutic agent (DHFR inhibitor) currently under investigation in
patients with non-small cell lung cancer and Non-Hodgkin's lymphoma; and
RH1, a small molecule chemotherapeutic agent bioactivated by the enzyme
DT-diaphorase currently under evaluation in patients with advanced solid
tumors. For more information, please visit the Company's web site at:
http://www.allos.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking statements
that involve significant risks and uncertainties, including those to be
discussed in the presentation and others that can be found in the "Risk
Factors" section of the Company's Form 10-K for the year ended December 31,
2005 and in the Company's periodic reports on Form 10-Q and Form 8-K. The
Company does not undertake any obligation to update any forward-looking
statements contained in the anticipated presentation as a result of new
information, future events or otherwise. The Company cautions investors not
to place undue reliance on the forward-looking statements contained in the
presentation. No forward-looking statement can be guaranteed and actual
events and results may differ materially from those projected.
SOURCE Allos Therapeutics, Inc.
 back to top
Related links:
http://www.allos.com
CONTACT:
Jennifer Neiman, Manager, Corporate
Communications of Allos Therapeutics, +1-720-540-5227,
jneiman@allos.com
|
